Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 1, 1998, Pages 53-58

  Kobayashi, Kunihiko ^a,b   Shinbara, Ayako ^a   Kamimura, Mitsuhiro ^a   Takeda, Yuichiro ^a   Kudo, Koichiro ^a   Kabe, Junzaburo ^a   Hibino, Suguru ^b   Hino, Mitsunori ^b   Shibuya, Masahiko ^b   Kudoh, Shonji ^b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cisplatin; Irinotecan; Non small cell lung cancer; Pharmacokinetics; Weekly administration

Indexed keywords

CISPLATIN; IRINOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 7144254457     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050784     Document Type: Article

References (18)

1. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R. et al (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602
2. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N (1995) Evaluation nobel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer sublines resistant to cisplatin. Anticancer Res 15: 393
3. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T and the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16
4. Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinolecan (CPT-11) and characteristic mucozal changes in the mouse ileum and cecum. J Natl Cancer Inst 87: 1876
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intraceller roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187
6. Kobayashi K, Hino M, Niitani H (1989) Study of various platinum compounds on time-dependency for their cytotoxicity using human tumor clonogenic assay (HTCA). In: Rubinstein E, Adam D (eds) Recent advances in chemotherapy (Proceedings of the 16th International Congress of Chemotherapy). Jerusalem. E. Lewin-Eptein, p 723
7. Kobayashi K, Kudoh S, Takemoto T, Hino M, Hayashihara K, Nakahiro K, Ando M, Niitani H (1995) In vitro investigation of a combination of two drugs, eisplatin and carboplatin. as a function of the area under the c t curve. J Cancer Res Clin Oncol 121: 715
8. Kunimoto T, Nitta K, Tanaka T, Ueraha N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-pip-eridino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin. against murine tumors. Cancer Res 47: 5944
9. Masuda, N. Fukuoka, M, Kusunoki, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takeda M (1992) CPT-11: a new derivative of eamptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225
10. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775
11. Matsumoto N, Nakao S, Esaki T, Fujishima H, Tatsumoto T, Niho Y (1995) Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62: 70
12. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sasaki Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K. (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907
13. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M (1988) Cell killing action of cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21: 185
14. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM. et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633
15. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N and the CPT-11 Gastrointestinal Cancer Study Group (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909
16. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai F, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Res 56: 3752
17. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio Dym 14: 341
18. Yoneda S, Noguchi Y, Sakai H (1996) Chemotherapy for outpatients with lung cancer (in Japanese). Kagakuryoho No Ryoiki 12: 481